Last updated:
5/6/2024
Years published: 1996, 2002, 2024
NORD gratefully acknowledges Gioconda Alyea, MD (FMG), MS, National Organization for Rare Disorders for assistance in the preparation of this report.
Oculocerebral syndrome with hypopigmentation is an extremely rare genetic disorder characterized by the lack of normal color (hypopigmentation) of the skin and hair and abnormalities of the central nervous system that affect the eyes and certain parts of the brain (oculocerebral).
Some signs and symptoms are evident at birth (congenital) and may include an unusually light skin color and silvery-gray hair, small eyes (microphthalmia) and other eye abnormalities as clouding (opacities) of the front, clear portion of the eye (cornea) and/or rapid, involuntary eye movements (nystagmus). Additional symptoms that may develop during infancy include involuntary muscle contractions, associated loss of muscle function (spastic paraplegia), developmental delays and/or intellectual disability.
Inheritance is thought to be autosomal recessive, but the underlying genetic cause of this condition is still unknown. Treatment is directed toward the specific symptoms that the affected person has.
Oculocerebral syndrome with hypopigmentation, also known as Cross syndrome, is an extremely rare genetic disorder that may be apparent at birth (congenital) or during early infancy.
Abnormally small eyes and lack of skin and hair color are usually apparent at birth. Neurological abnormalities may become apparent by three months of age. Some affected infants have abnormally enlarged gums (gingival fibromatosis) when the first teeth emerge from the gums (at age six months to three years). Other symptoms may become apparent later during infancy or childhood.
Reported signs and symptoms include:
The gene involved in this syndrome is not yet known, but one report suggested that the gene associated with this condition is located on chromosome 3 at 3q27.1q29.
Inheritance
Oculocerebral syndrome with hypopigmentation is thought to be inherited in an autosomal recessive pattern. Recessive genetic disorders occur when an individual inherits a disease-causing gene variant from each parent. If an individual receives one normal gene and one disease-causing gene variant, the person will be a carrier for the disease, but usually will not show symptoms. The risk for two carrier parents to both pass the gene variant and have an affected child is 25% with each pregnancy. The risk of having a child who is a carrier like the parents is 50% with each pregnancy. The chance for a child to receive normal genes from both parents is 25%. The risk is the same for males and females.
Parents of several individuals with this disorder have been closely related by blood (consanguineous). In these families, there is a higher-than-normal chance that both parents carry, and consequently may pass on, the gene variants that cause this disorder.
Oculocerebral syndrome with hypopigmentation is an extremely rare disorder that affects males and females in equal numbers. It was first reported in 1967 and, as of 2024, fewer than 20 cases have been described, without an ethnic preference. Most reported cases occurred within families.
Oculocerebral syndrome with hypopigmentation may be suspected in infants with characteristic neurological and ocular abnormalities occurring in association with the presence of abnormally light skin and silvery-gray hair.
Abnormal lack of skin color (cutaneous hypopigmentation) and abnormally small eye(s) are usually obvious at birth or in early infancy. Ultrasonography may be used to confirm a diagnosis of small eyes (microphthalmia). Horizontal side-to-side eye movements (nystagmus) and outward turning of the eyelids (ectropion palpebral conjunctivae) may also be observed at birth. Enlarged gums (gingival fibromatosis) may develop when the first teeth emerge from the gums (usually around six months to three years of age). Neurological abnormalities, such as athetoid movements and ataxia, may become apparent around three months of age. Other symptoms (e.g., developmental delays, intellectual disability, etc.) may not become apparent until late infancy or childhood.
Internal abnormalities such as an underdeveloped diaphragm (oligophrenia) may be detected through a combination of observation and internal imaging techniques, such as computerized tomography (CT) scanning. CT scanning is an imaging technique in which a computer and X-rays are used to create a film showing cross-sectional images of certain organs.
Diagnosis of oculocerebral syndrome with hypopigmentation may be confirmed based upon a thorough clinical evaluation and detailed patient history, characteristic physical findings, specialized laboratory tests and imaging techniques.
There is no cure or specific treatment. The treatment is symptomatic and supportive, and it is directed toward the specific symptoms that are apparent in each individual. Treatment may require the coordinated efforts of a team of specialists. Pediatricians, dentists, physicians who specialize in disorders of the eyes (ophthalmologists), physicians who specialize in skin disorders (dermatologists), and other health care professionals may need to plan an affected child’s treatment systematically and comprehensively.
An affected child’s skin may be highly sensitive to sun exposure; therefore, sunscreen, hats, and long sleeves may be recommended to avoid sunburn. Wearing sunglasses and other preventative measures may also be recommended to protect affected individuals from the sun.
Corrective glasses or contact lenses may be used to help improve vision. In some patients, eye surgery may be performed.
The size of the gums may be reduced with surgery. However, the enlargement may recur as more teeth emerge and/or when secondary teeth grow in, requiring other surgeries.
Early intervention is important to ensure that affected children reach their potential. Special services that may be beneficial to affected children may include special remedial education and other medical, social and/or vocational services.
Genetic counseling is recommended for families of affected children.
Information on current clinical trials is posted on the Internet at https://clinicaltrials.gov/. All studies receiving U.S. Government funding, and some supported by private industry, are posted on this government web site.
For information about clinical trials being conducted at the NIH Clinical Center in Bethesda, MD, contact the NIH Patient Recruitment Office:
Toll-free: (800) 411-1222
TTY: (866) 411-1010
Email: [email protected]
Some current clinical trials also are posted on the following page on the NORD website:
https://rarediseases.org/living-with-a-rare-disease/find-clinical-trials/
For information about clinical trials sponsored by private sources, contact:
https://www.centerwatch.com/
For information about clinical trials conducted in Europe, contact:
https://www.clinicaltrialsregister.eu/
TEXTBOOKS
Scriver CR, et al., eds. The Metabolic and Molecular Basis of Inherited Disease. 7th Ed. New York, NY; McGraw-Hill Companies, Inc; 1995:4379.
Champion RH, et al., eds. Textbook of Dermatology. 5th ed. Cambridge, MA: Blackwell Scientific Publications; 1992:1605, 2668, 2705.
Buyse ML, ed. Birth Defects Encyclopedia. Dover, MA: Blackwell Scientific Publications; For: The Center for Birth Defects Information Services Inc; 1990:81, 660-62, 775, 778-79.
JOURNAL ARTICLES
Liu S, Kuht HJ, Moon EH, Maconachie GDE, Thomas MG. Current and emerging treatments for albinism. Surv Ophthalmol. 2021 Mar-Apr;66(2):362-377. https://www.sciencedirect.com/science/article/abs/pii/S0039625720301454
Gironi LC, Zottarelli F, Savoldi G, Notarangelo LD, Basso ME, Ferrero I, Timeus F, Fagioli F, Maiuri L, Colombo E, Savoia P. Congenital hypopigmentary disorders with multiorgan impairment: A case report and an overview on gray hair syndromes. Medicina (Kaunas). 2019 Mar 25;55(3):78. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6473230/
Chabchoub E, Cogulu O, Durmaz B, Vermeesch JR, Ozkinay F, Fryns JP. Oculocerebral hypopigmentation syndrome maps to chromosome 3q27.1q29. Dermatology. 2011;223(4):306-10. https://pubmed.ncbi.nlm.nih.gov/22327602/
Tezcan I, et al. A new case of oculocerebral hypopigmentation syndrome (Cross syndrome) with additional findings. Clin Genet. 1997;51:118-21.
Lerone M, et al. Oculocerebral syndrome with hypopigmentation (Cross syndrome): report of a new case. Clin Genet. 1992;41:87-89.
De Jong G, et al. Oculocerebral syndrome with hypopigmentation (Cross syndrome): the mixed pattern of hair pigmentation as an important diagnostic sign. Genet Couns. 1991;2:151-55.
Ozkan H. Oculocerebral hypopigmentation syndrome (Cross syndrome). Turk J Pediatr. 1991;33:247-52.
Courtens W, et al. Oculocerebral hypopigmentation syndrome (Cross syndrome) in a gipsy child. Acta Pediatr Scand. 1989;78:806-10.
Castle DJ, et al. The oculocerebral syndrome in association with generalised hypopigmentation. A case report. S Afr Med J. 1989;76:35-56.
Fryns JP, et al. Oculocerebral syndrome with hypopigmentation (Cross syndrome). Report of two siblings born to consanguineous parents. Clin Genet. 1988;34:81-84.
Patton MA, et al. An oculocerebral hypopigmentation syndrome: a case report with clinical, histochemical, and ultrastructural findings. J Med Genet. 1987;24:118-22.
Preus M, et al. An oculocerebral hypopigmentation syndrome. J Genet Hum. 1983;31:323-28.
Cross HE, et al. A new oculocerebral syndrome with hypopigmentation. J Pediatr. 1967;70:398-406.
INTERNET
Oculocerebral syndrome with hypopigmentation. Online Mendelian Inheritance in Man (OMIM). Baltimore. MD: The Johns Hopkins University; Entry No: 257800; Last Update: 11/11/2013. https://www.omim.org/entry/257800 Accessed March 4, 2024.
NORD strives to open new assistance programs as funding allows. If we don’t have a program for you now, please continue to check back with us.
NORD and MedicAlert Foundation have teamed up on a new program to provide protection to rare disease patients in emergency situations.
Learn more https://rarediseases.org/patient-assistance-programs/medicalert-assistance-program/Ensuring that patients and caregivers are armed with the tools they need to live their best lives while managing their rare condition is a vital part of NORD’s mission.
Learn more https://rarediseases.org/patient-assistance-programs/rare-disease-educational-support/This first-of-its-kind assistance program is designed for caregivers of a child or adult diagnosed with a rare disorder.
Learn more https://rarediseases.org/patient-assistance-programs/caregiver-respite/The information provided on this page is for informational purposes only. The National Organization for Rare Disorders (NORD) does not endorse the information presented. The content has been gathered in partnership with the MONDO Disease Ontology. Please consult with a healthcare professional for medical advice and treatment.
The Genetic and Rare Diseases Information Center (GARD) has information and resources for patients, caregivers, and families that may be helpful before and after diagnosis of this condition. GARD is a program of the National Center for Advancing Translational Sciences (NCATS), part of the National Institutes of Health (NIH).
View reportOrphanet has a summary about this condition that may include information on the diagnosis, care, and treatment as well as other resources. Some of the information and resources are available in languages other than English. The summary may include medical terms, so we encourage you to share and discuss this information with your doctor. Orphanet is the French National Institute for Health and Medical Research and the Health Programme of the European Union.
View reportOnline Mendelian Inheritance In Man (OMIM) has a summary of published research about this condition and includes references from the medical literature. The summary contains medical and scientific terms, so we encourage you to share and discuss this information with your doctor. OMIM is authored and edited at the McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine.
View report